Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 149
Filter
1.
Environ Monit Assess ; 193(3): 112, 2021 Feb 05.
Article in English | MEDLINE | ID: mdl-33543341

ABSTRACT

The mainly agricultural input of NO3- and compliance with drinking water guideline values pose major challenges for many water suppliers. Additionally, associated changes in hydrochemistry, especially concerning products of NO3- reduction (Fe2+/3+, Mn2+/4+, Ca2+, Mg2+, SO42-, HCO3-) and subsequent reactions, can have a major influence on mineral saturation states and well yield: well productivity can be strongly reduced by mineral precipitation and silting. To evaluate hydrogeochemical evolution and clogging potential for a given well field, thorough hydrochemical and geochemical investigations are required. Therefore, time-dependent and depth-specific ion concentrations in water samples (n = 818) were analysed in a catchment area of a waterworks in western Germany. The sediments of the aquifers were extensively investigated for their geochemistry (CS, scanning electron microscope, aqua regia digestion and dithionite solution; n = 253). In addition, PhreeqC was used to model saturation indices in order to identify possible mineral precipitation in the wells. Results show a high NO3- input into deep wells screened in Tertiary sediments due to an admixture of Quaternary groundwater. Directly at the Quaternary-Tertiary boundary, chemolithotrophic NO3- reduction consuming pyrite occurs. Protons released during the process are pH-buffered by dissolving carbonate minerals. Overall, the hydrochemistry and especially the saturation indices are strongly influenced by NO3- reduction and its degradation products. A change in well yield has not yet been observed, but future clogging by ochre formation or sintering cannot be excluded.


Subject(s)
Groundwater , Water Pollutants, Chemical , Environmental Monitoring , Germany , Nitrates/analysis , Water Pollutants, Chemical/analysis , Water Wells
2.
Heart Vessels ; 36(3): 408-413, 2021 Mar.
Article in English | MEDLINE | ID: mdl-32951086

ABSTRACT

Rates of permanent pacemaker (PPM) implantation following transcatheter aortic valve implantation (TAVI) are higher than following surgery and are dependent on patient factors and valve type. There is an increasing trend towards pre-emptive PPM insertion in patients with significant conduction disease prior to TAVI. We report results from the British Cardiovascular Intervention Society (BCIS) on pre- and post-procedural PPM implantation in the TAVI population. All centres in the United Kingdom performing TAVI are required to submit data on all TAVI procedures to the National database which are then reported annually. During 2015, there were 2373 TAVI procedures in the UK. 22.4% of TAVI patients had a PPM implanted either pre-procedure (including the distant past), or during the in-hospital procedural episode. Of these, 7.9% were pre-procedure and 14.5% post-procedure. Overall PPM rates were Edwards Sapien (13.5%), Medtronic CoreValve (28.2%) and Boston Lotus (42.1%; p < 0.01). Pre-procedure pacing rates were Edwards Sapien (6.0%), Medtronic CoreValve (9.1%) and Boston Lotus (12.3%; p < 0.01). Pre-procedural pacing rates for the Boston Lotus valve have risen year-on-year from 5.8% (2013) to 8.6% (2014) to 12.3% (2015). The UK TAVI Registry demonstrates a pre-procedural permanent pacing bias amongst patients receiving transcatheter valves with higher post-procedure pacing rates. Pre-emptive permanent pacing is likely to be responsible for this difference.


Subject(s)
Aortic Valve Stenosis/surgery , Aortic Valve/surgery , Bundle-Branch Block/therapy , Electrocardiography , Preoperative Care/methods , Registries , Transcatheter Aortic Valve Replacement , Aged, 80 and over , Aortic Valve Stenosis/complications , Aortic Valve Stenosis/diagnosis , Bundle-Branch Block/complications , Bundle-Branch Block/physiopathology , Cardiac Pacing, Artificial , Female , Follow-Up Studies , Humans , Male , Retrospective Studies , Risk Factors , Time Factors , Treatment Outcome , United Kingdom
3.
Int J Cardiol ; 302: 1-4, 2020 03 01.
Article in English | MEDLINE | ID: mdl-31864788

ABSTRACT

BACKGROUND: The Rapid Access Chest Pain Clinic (RACPC) has become an important means of assessing patients who present with ischaemic or ischaemia-like symptoms of recent onset. Observations have shown that up to 70% are discharged with a diagnosis of non-anginal chest pain (NACP) and accordingly "reassured". This study aims to describe the actual clinical outcomes of this cohort of patients discharged from the RACPC. METHODS: We undertook a single centre retrospective cohort study at a tertiary cardiac hospital. The outcomes of unselected patients diagnosed with NACP and discharged from the RACPC between April 2010 and March 2013 at University Hospitals of Leicester (UHL) were recorded. Re-referrals to cardiology outpatient clinic and emergency hospital admissions for cardiovascular disease within 6 months, and the mortality rate at 12 months, were determined. RESULTS: 7066 patients were seen in the UHL RACPC during the 36-month period. 3253 (46.0%) were diagnosed with NACP and discharged. 7 (0.2%) were diagnosed with coronary artery disease (CAD) and 8 (0.25%) cases of acute coronary syndrome (ACS) identified during the review period. 11 (0.3%) patients died within 12 months of discharge from RACPC. No deaths were attributable to CAD. CONCLUSIONS: Comprehensive assessment using risk-stratification criteria in a nurse practitioner-led RACPC can accurately identify patients who are at low-risk for subsequent CAD. Despite contemporary National Institute for Health and Care Excellence (NICE) guidelines that shift focus away from a clinical judgement based approach, this strategy appears to robustly predict favourable outcomes in patients diagnosed with NACP.


Subject(s)
Chest Pain/diagnosis , Coronary Artery Disease/diagnosis , Pain Clinics/statistics & numerical data , Patient Discharge/trends , Adult , Aged , Angina Pectoris , Chest Pain/etiology , Coronary Artery Disease/complications , Female , Follow-Up Studies , Humans , Male , Middle Aged , Retrospective Studies
4.
J Cardiothorac Surg ; 11(1): 159, 2016 Nov 29.
Article in English | MEDLINE | ID: mdl-27899128

ABSTRACT

OBJECTIVE: Transcatheter aortic valve implantation (TAVI) has been adopted rapidly in Europe. TAVI national registries can augment understanding of technologies and represent real-world experience, providing further clinical insights. We undertook a meta-analysis of published European national TAVI registries to assess current results following TAVI in Europe. METHODS: Electronic databases were searched. The review focused on the comparison of the following TAVI strategies: transfemoral (TF) and transapical (TA) SAPIEN and CoreValve implantation. Individual event rates for outcomes of interest were pooled using a mixed effect model. RESULTS: Seven European national TAVI registries (UK, Swiss, Belgium, Italy, Spain, France, Germany) were identified, including a total of 9786 patients who received TF-SAPIEN (n = 2885), TA-SAPIEN (n = 2252) and CoreValve (n = 4649) implantation. Pooled incidence of 30-day mortality was 0.08% [95% Confidence Interval (CI): 0.05-0.11], 0.12% [95% CI: 0.07-0.19] and 0.06% [95% CI: 0.03-0.11] for TF-SAPIEN, TA-SAPIEN and CoreValve respectively (test for subgroup difference P = 0.18); there was high heterogeneity across European countries. Pooled incidence of stroke was comparable among the TAVI strategies (test for subgroup difference P = 0.79); the incidence of post-procedural moderate paravalvular leak ≥ 2 (P = 0.9) was similar across groups. CoreValve implantation was associated with an increased risk of pacemaker implantation (0.22 [95% CI: 0.19-0.26]; test for subgroup difference P < 0.0001). The lowest 30-day mortality was associated with TAVI performed in Spain (b coefficient -4.3; P = 0.03), in Italy (b coefficient -2.1; P < 0.0001), in UK (b coefficient -1.95; P = 0.01) and in France (b coefficient -2.8; P = 0.03). The German registry has the highest mortality for every TAVI strategy amongst all other European registries and especially for the TA-SAPIEN group. CONCLUSIONS: Transarterial TAVI approaches were associated with a low early mortality regardless of the type of device used. There was marked heterogeneity among European countries for early mortality.


Subject(s)
Aortic Valve Stenosis/surgery , Aortic Valve/surgery , Heart Valve Prosthesis , Stroke/epidemiology , Transcatheter Aortic Valve Replacement/methods , Aortic Valve Stenosis/mortality , Europe/epidemiology , Heart Valve Prosthesis/adverse effects , Humans , Incidence , Pacemaker, Artificial/statistics & numerical data , Registries , Transcatheter Aortic Valve Replacement/adverse effects , Transcatheter Aortic Valve Replacement/mortality , Treatment Outcome
5.
Minerva Cardioangiol ; 63(5): 449-56, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26158289

ABSTRACT

Transradial access has nowadays become a standard of care for percutaneous coronary angiography and intervention. This approach has demonstrated significant reduction in bleeding rate, length of hospital stay, and improvement in clinical outcomes when compared to the traditional transfemoral approach. Due to its advantages this new access is also increasingly being used in non-coronary visceral or peripheral interventions. However, this novel approach may lead to severe catheter kinking and twisting and further manipulation may be required to unravel the catheter and avoid complication. Purpose of this technical review is to present the current techniques and trends in preventing and resolving issues related to radial access catheter kinks.


Subject(s)
Cardiac Catheterization/methods , Coronary Angiography/methods , Percutaneous Coronary Intervention/methods , Cardiac Catheterization/adverse effects , Coronary Disease/diagnostic imaging , Coronary Disease/therapy , Hemorrhage/epidemiology , Humans , Length of Stay , Radial Artery
6.
Endoscopy ; 43(8): 716-22, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21811940

ABSTRACT

BACKGROUND AND STUDY AIMS: The aim of the present study was to perform a risk analysis during the implementation phase of nurse-administered propofol sedation (NAPS) and to validate our structured training program. PATIENTS AND METHODS: A structured training program was developed both for endoscopists and for endoscopy nurses who were administering propofol sedation. The nurses' program comprised a 6-week course including theoretical and practical training in airway management, and the endoscopists' program consisted of 2.5 h of theory and a short course in practical airway management. In the implementation phase, data from 1822 endoscopic procedures in 1764 patients were prospectively collected. All adverse events related to sedation were recorded (defined as oxygen saturation < 92%, airway handling, assisted ventilation, need for intubation, change in blood pressure > 20 mmHg). RESULTS: 78 cases of hypoxemia were documented in 1764 patients (4.4%), in 56/983 upper endoscopies (5.7%) and 22/754 lower endoscopies (2.9%) (P = 0.007). Assisted ventilation was necessary in 19 cases (1.1%) and anesthesiologic assistance was requested 10 times. Two patients required endotracheal intubation. A change in blood pressure was recorded in 451 patients (26%). Independent risk factors were type of intervention and level of experience of the staff performing the sedation. CONCLUSION: These results were obtained after development of a structured training program both for endoscopists and nurses using propofol for sedation, and can be used as basis for further comparison. NAPS for endoscopic procedures is safe when performed by personnel properly trained in airway handling and sedation with propofol, and has considerable advantages compared with conventional sedation for endoscopy.


Subject(s)
Deep Sedation/adverse effects , Deep Sedation/nursing , Hypnotics and Sedatives/administration & dosage , Propofol/administration & dosage , Adult , Aged , Cholangiopancreatography, Endoscopic Retrograde/adverse effects , Cholangiopancreatography, Endoscopic Retrograde/methods , Cholangiopancreatography, Endoscopic Retrograde/nursing , Clinical Competence , Deep Sedation/methods , Education, Nursing, Continuing , Endoscopy, Gastrointestinal/adverse effects , Endoscopy, Gastrointestinal/methods , Endoscopy, Gastrointestinal/nursing , Female , Humans , Hypotension/etiology , Hypoxia/etiology , Hypoxia/therapy , Male , Middle Aged , Risk Assessment
7.
Heart ; 96(10): 736-40, 2010 May.
Article in English | MEDLINE | ID: mdl-20448123

ABSTRACT

Periprocedural myocardial injury (PMI) is common after percutaneous coronary intervention (PCI). Periprocedural infarction (myocardial infarction type 4a) occurs after at least 10% of PCI procedures and has an impact on long-term prognosis. Measurement of biomarkers to allow assessment of PMI is an important tool for clinical and research purposes and should be routine after every PCI (troponin I or T and CK-MB). The importance of oral and intravenous antiplatelet agents and other drugs which have been proven to reduce PMI is discussed.


Subject(s)
Angioplasty, Balloon, Coronary/adverse effects , Heart Injuries/etiology , Biomarkers/blood , Cardiotonic Agents/therapeutic use , Heart Injuries/prevention & control , Humans , Myocardial Infarction/etiology , Myocardial Infarction/prevention & control , Platelet Aggregation Inhibitors/therapeutic use
9.
QJM ; 103(6): 367-77, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20211848

ABSTRACT

Thienopyridines are a class of drug targeting the platelet adenosine diphosphate 2 receptor. They have been shown to significantly reduce platelet activity exerting an important role in those clinical settings in which such an effect is beneficial. Ticlopidine was first to be introduced several years ago but it was quickly replaced by clopidogrel as it had a better risk/benefit profile. Recently, prasugrel has been developed and tested in several ex vivo studies and clinical trials showing able to provide a more powerful antiplatelet effect at the expense of a higher risk of bleeding complications. Great debate rose around its recent approval in the US as well as in Europe. This review aims at exploring the development and available clinical data of this third-generation thienopyridine while discussing its practical implementation in routine practice.


Subject(s)
Piperazines/therapeutic use , Platelet Aggregation Inhibitors/therapeutic use , Receptors, Purinergic P2/therapeutic use , Thiophenes/therapeutic use , Ticlopidine/analogs & derivatives , Clopidogrel , Drug Evaluation, Preclinical , Hemorrhage/complications , Humans , Piperazines/antagonists & inhibitors , Piperazines/pharmacokinetics , Platelet Aggregation Inhibitors/pharmacokinetics , Prasugrel Hydrochloride , Purinergic P2 Receptor Antagonists , Randomized Controlled Trials as Topic , Risk Factors , Thiophenes/antagonists & inhibitors , Thiophenes/pharmacokinetics , Ticlopidine/pharmacokinetics , Ticlopidine/therapeutic use
11.
BMJ Case Rep ; 20102010 Oct 03.
Article in English | MEDLINE | ID: mdl-22767565

ABSTRACT

We present a case of a 43-year-old lady who presented with an acute coronary syndrome, but without any cardiac risk factors or previous cardiac symptoms, and who had a spontaneous coronary artery dissection. This was successfully treated with percutaneous coronary intervention. A brief discussion of this clinical entity and literature review is presented.


Subject(s)
Acute Coronary Syndrome/diagnosis , Angioplasty, Balloon, Coronary/methods , Aortic Dissection/diagnosis , Coronary Aneurysm/diagnosis , Acute Coronary Syndrome/therapy , Adult , Aortic Dissection/diagnostic imaging , Aortic Dissection/therapy , Chest Pain/diagnosis , Chest Pain/etiology , Coronary Aneurysm/diagnostic imaging , Coronary Aneurysm/therapy , Coronary Angiography/methods , Coronary Stenosis/diagnostic imaging , Coronary Stenosis/surgery , Diagnosis, Differential , Female , Follow-Up Studies , Humans , Risk Assessment , Treatment Outcome
12.
Heart ; 95(23): 1937-43, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19687014

ABSTRACT

AIMS: Myocardial revascularisation improves outcomes in patients with coronary artery disease. However, these procedures may themselves cause irreversible myocardial injury. The prognostic value of procedural myocardial injury is uncertain. METHODS AND RESULTS: We quantified procedural myocardial necrosis using delayed enhancement cardiovascular magnetic resonance imaging (DE-CMR) in 152 consecutive patients before and shortly after percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG). The primary endpoint was defined as death, non-fatal myocardial infarction, sustained ventricular arrhythmia, unstable angina or heart failure requiring hospitalisation. During a median follow-up of 2.9 years, 27 patients (18%) reached the primary endpoint. 49 patients (32%) had evidence of new procedure-related myocardial hyperenhancement with a median mass of 5.0 g (interquartile range 2.7-9.8). After adjustment for age and sex, these patients had a 3.1-fold (95% confidence interval 1.4 to 6.8; p = 0.004) higher risk of adverse outcome than patients without new hyperenhancement. Cardiac troponin levels and quantitative measures of left ventricular function after procedure did not show any significant independent association with the primary endpoint and they did not alter the independent association of new hyperenhancement. CONCLUSIONS: Myocardial injury during PCI or CABG, identified by DE-CMR, adversely affects clinical outcome. This suggests the benefits from revascularisation could partially be offset by new myocardial injury caused by the intervention itself.


Subject(s)
Acute Coronary Syndrome/therapy , Angina Pectoris/therapy , Angioplasty, Balloon, Coronary/adverse effects , Coronary Artery Bypass/adverse effects , Myocardial Reperfusion Injury/diagnosis , Acute Coronary Syndrome/mortality , Angina Pectoris/mortality , Angioplasty, Balloon, Coronary/mortality , Coronary Artery Bypass/mortality , Female , Humans , Kaplan-Meier Estimate , Magnetic Resonance Angiography/methods , Magnetic Resonance Angiography/mortality , Male , Middle Aged , Myocardial Infarction/diagnosis , Myocardial Infarction/mortality , Myocardial Infarction/therapy , Myocardial Reperfusion Injury/etiology , Myocardial Reperfusion Injury/mortality , Prognosis
13.
Br J Pharmacol ; 157(5): 769-80, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19422386

ABSTRACT

BACKGROUND AND PURPOSE: Although carbon monoxide (CO) can modulate inflammatory processes, the influence of CO on adhesion molecules is less clear. This might be due to the limited amount of CO generated by haem degradation. We therefore tested the ability of a CO releasing molecule (CORM-3), used in supra-physiological concentrations, to modulate the expression of vascular cell adhesion molecule (VCAM)-1 and E-selectin on endothelial cells and the mechanism(s) involved. EXPERIMENTAL APPROACH: Human umbilical vein endothelial cells (HUVECs) were stimulated with tumour necrosis factor (TNF)-alpha in the presence or absence of CORM-3. The influence of CORM-3 on VCAM-1 and E-selectin expression and the nuclear factor (NF)-kappaB pathway was assessed by flow cytometry, Western blotting and electrophoretic mobility shift assay. KEY RESULTS: CORM-3 inhibited the expression of VCAM-1 and E-selectin on TNF-alpha-stimulated HUVEC. VCAM-1 expression was also inhibited when CORM-3 was added 24 h after TNF-alpha stimulation or when TNF-alpha was removed. This was paralleled by deactivation of NF-kappaB and a reduction in VCAM-1 mRNA. Although TNF-alpha removal was more effective in this regard, VCAM-1 protein was down-regulated more rapidly when CORM-3 was added. CORM-3 induced haem oxygenase-1 (HO-1) in a dose- and time-dependent manner, mediated by the transcription factor, Nrf2. CORM-3 was still able to down-regulate VCAM-1 expression in HUVEC transfected with siRNA for HO-1 or Nrf2. CONCLUSIONS AND IMPLICATIONS: Down-regulation of VCAM and E-selectin expression induced by CORM-3 was independent of HO-1 up-regulation and was predominantly due to inhibition of sustained NF-kappaB activation.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Carbon Monoxide/metabolism , E-Selectin/metabolism , Endothelial Cells/drug effects , Heme Oxygenase-1/metabolism , Organometallic Compounds/pharmacology , Vascular Cell Adhesion Molecule-1/metabolism , Cells, Cultured , Dose-Response Relationship, Drug , Down-Regulation , E-Selectin/genetics , Endothelial Cells/enzymology , Heme Oxygenase-1/genetics , Humans , NF-E2-Related Factor 2/metabolism , NF-kappa B/metabolism , Promoter Regions, Genetic/drug effects , RNA Interference , RNA, Messenger/metabolism , Time Factors , Transfection , Tumor Necrosis Factor-alpha/metabolism , Vascular Cell Adhesion Molecule-1/genetics
14.
QJM ; 102(6): 369-78, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19286891

ABSTRACT

AIM: Elevation of Troponin after scheduled percutaneous coronary intervention (PCI) is a recognized consequence. We sought to evaluate the prognostic significance and impact of the newly published definition of PCI-related myocardial infarction (MI) according to which any troponin elevation >3 times the upper reference limit identify a peri-procedural MI. METHODS: Search of BioMedCentral, CENTRAL, mRCT and PubMed (updated May 2008). Outcomes of interest were: MACE [the composite of all cause death, MI, repeat target vessel PCI (re-PCI) and coronary artery bypass grafting (CABG)]; single end points were also assessed. RESULTS: Fifteen studies have been included totalling 7578 patients. Troponin elevation occurred in 28.7% of the procedures. The incidence of PCI-related MI according to the new definition was 14.5%. During the hospitalization, any level of raised troponin was associated with an increased risk of MACE [OR 11.29 (3.00-42.48), Number needed to harm (NNH) 5], death [OR 7.16 (1.95-26.27), NNH = 100], MI [OR 30.85 (6.05-157.38), NNH = 4] and re-PCI [OR 4.13 (1.23-13.88), NNH = 50]. Patients with PCI-related MI had an increased risk of death [OR 17.25 (2.71-109.96), NNH = 100] and re-PCI [OR 10.86 (3.2-36.94), NNH = 25]. At follow up of 18 months any troponin elevation was associated with an increased risk of MACE [OR 1.48 (1.12-1.96), NNH = 20], death [OR 2.19 (1.59-3.00), NNH = 50], MI [OR 3.29 (2.71-6.31), NNH = 33] and re-PCI [OR 1.47 (1.06-2.03), NNH = 25]. In patients with PCI-related MI the risk of MACE was further increased: OR 2.25 (1.26-4.00), NNH = 3. An increase of the troponin level below the cut-off was not associated with MACE. CONCLUSION: A diagnosis of MI according to the new guidelines applies to 15% of patients undergoing PCI and these patients are at high risk of further adverse events both during the hospital stay and at 18 months.


Subject(s)
Coronary Artery Bypass/adverse effects , Myocardial Infarction/diagnosis , Troponin/blood , Angioplasty, Balloon, Coronary , Biomarkers/blood , Epidemiologic Methods , Humans , Myocardial Infarction/epidemiology , Myocardial Infarction/mortality , Risk Factors , Time Factors , Treatment Outcome
17.
Lancet ; 372(9656): 2132-42, 2008 Dec 20.
Article in English | MEDLINE | ID: mdl-19041130

ABSTRACT

BACKGROUND: The effect of carotid endarterectomy in lowering the risk of stroke ipsilateral to severe atherosclerotic carotid-artery stenosis is offset by complications during or soon after surgery. We compared surgery under general anaesthesia with that under local anaesthesia because prediction and avoidance of perioperative strokes might be easier under local anaesthesia than under general anaesthesia. METHODS: We undertook a parallel group, multicentre, randomised controlled trial of 3526 patients with symptomatic or asymptomatic carotid stenosis from 95 centres in 24 countries. Participants were randomly assigned to surgery under general (n=1753) or local (n=1773) anaesthesia between June, 1999 and October, 2007. The primary outcome was the proportion of patients with stroke (including retinal infarction), myocardial infarction, or death between randomisation and 30 days after surgery. Analysis was by intention to treat. The trial is registered with Current Control Trials number ISRCTN00525237. FINDINGS: A primary outcome occurred in 84 (4.8%) patients assigned to surgery under general anaesthesia and 80 (4.5%) of those assigned to surgery under local anaesthesia; three events per 1000 treated were prevented with local anaesthesia (95% CI -11 to 17; risk ratio [RR] 0.94 [95% CI 0.70 to 1.27]). The two groups did not significantly differ for quality of life, length of hospital stay, or the primary outcome in the prespecified subgroups of age, contralateral carotid occlusion, and baseline surgical risk. INTERPRETATION: We have not shown a definite difference in outcomes between general and local anaesthesia for carotid surgery. The anaesthetist and surgeon, in consultation with the patient, should decide which anaesthetic technique to use on an individual basis. FUNDING: The Health Foundation (UK) and European Society of Vascular Surgery.


Subject(s)
Anesthesia, General , Anesthesia, Local , Carotid Stenosis/surgery , Postoperative Complications/mortality , Postoperative Complications/prevention & control , Stroke/mortality , Stroke/prevention & control , Aged , Carotid Stenosis/complications , Endarterectomy, Carotid , Female , Humans , Male , Postoperative Complications/etiology , Stroke/etiology
19.
J Thorac Cardiovasc Surg ; 136(4): 884-93, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18954626

ABSTRACT

OBJECT: Pexelizumab is a humanized monoclonal antibody inhibiting C5 complement. It has been postulated to improve outcomes in patients undergoing coronary artery bypass surgery and urgent reperfusion therapy for ST elevation myocardial infarction. We aimed at evaluating the risk/benefit profile of pexelizumab (bolus + infusion) versus placebo on top of current approaches in the management of patients with ST elevation myocardial infarction or undergoing coronary artery bypass. METHODS: We conducted a search of BioMedCentral, CENTRAL, mRCT, and PubMed without language restrictions (updated October 2007) for randomized controlled trials. Outcomes of interest were the risk of major adverse events (the composite of all-cause death, myocardial infarction, and thromboembolic stroke), the risk of single end points, and heart failure. RESULTS: Seven trials were included (15,196 patients: 7019 patients with ST elevation myocardial infarction and 8177 undergoing coronary bypass surgery). No benefit of adding pexelizumab was found in the overall analysis for major adverse events (OR 0.91 [0.76-1.09]; P = .29], death (OR 0.79 [0.61-1.03], P = .11], myocardial infarction (OR 1.04 [0.89-1.22]; P = .14), stroke (OR 0.95 [0.66-1.38]; P = .8), heart failure (OR1.0 [0.82-1.22]; P = .99), nor in the settings of patients with ST elevation myocardial infarction treated with mechanical or pharmacologic reperfusion therapy. Pexelizumab was associated with a 26% reduction of the risk of death in the setting of coronary artery bypass (OR 0.74 [0.58-0.94]; P = .01). The number needed to treat was 100. CONCLUSION: Our data ruled out the hypothesis of any benefit of adding pexelizumab on top of currently available therapies for ST elevation myocardial infarction. However, pexelizumab reduces the risk of death in patients undergoing coronary artery bypass grafting.


Subject(s)
Antibodies, Monoclonal/administration & dosage , Complement Inactivating Agents/administration & dosage , Coronary Artery Bypass/mortality , Myocardial Infarction/drug therapy , Myocardial Infarction/mortality , Adult , Aged , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal, Humanized , Combined Modality Therapy , Confidence Intervals , Coronary Angiography , Coronary Artery Bypass/methods , Dose-Response Relationship, Drug , Drug Administration Schedule , Electrocardiography , Female , Humans , Infusions, Intravenous , Male , Middle Aged , Myocardial Infarction/diagnosis , Myocardial Infarction/surgery , Myocardial Ischemia/diagnosis , Myocardial Ischemia/drug therapy , Myocardial Ischemia/mortality , Myocardial Ischemia/surgery , Odds Ratio , Prognosis , Randomized Controlled Trials as Topic , Reference Values , Risk Assessment , Severity of Illness Index , Single-Chain Antibodies , Survival Analysis , Treatment Outcome
20.
QJM ; 101(12): 915-25, 2008 Dec.
Article in English | MEDLINE | ID: mdl-18676683

ABSTRACT

Since their introduction several years ago, the 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitors-the statins-have been widely used for hyperlipidemia and for the primary/secondary prevention of cardiovascular diseases. They have been shown to be safe as well as efficacious in a number of different clinical trials; however, studies have suggested that they can interact with other co-administered therapies. More recently, the thienopyridines have been successfully integrated with the conventional medical treatment of coronary disease as they showed effectiveness in reducing platelet activity both in stable and unstable settings. They also improve the outcome of patients treated with percutaneous coronary intervention. The potential interaction of statins and thienopyridines is a matter of concern. Despite some preclinical data suggesting an interaction between statins metabolized by the liver cytochrome P3A4-such as atorvastatin, lovastatin and simvastatin-and clopidogrel, there is no compelling clinical evidence to stop their co-administration.


Subject(s)
Hydroxymethylglutaryl-CoA Reductase Inhibitors , Hypercholesterolemia/drug therapy , Platelet Aggregation Inhibitors , Ticlopidine/analogs & derivatives , Clopidogrel , Drug Interactions , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacokinetics , Platelet Aggregation Inhibitors/adverse effects , Platelet Aggregation Inhibitors/pharmacokinetics , Ticlopidine/adverse effects , Ticlopidine/pharmacokinetics
SELECTION OF CITATIONS
SEARCH DETAIL
...